Patent classifications
C08B37/00
ENTEROCOCCUS FAECALIS AND/OR ENTEROCOCCUS FAECIUM ANTIGEN
The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium. More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula:
##STR00001##
Product comprising polysaccharide derivatives
The disclosure relates to products including a polysaccharide derivative wherein the polysaccharide derivative includes a polysaccharide substituted with at least one of: a) at least one sulfate group; b) at least one sulfonate group; c) at least one thiosulfate group; or d) a combination thereof; wherein the polysaccharide is poly alpha-1,3-glucan, poly alpha-1,6-glucan, poly alpha-1,3-1,6-glucan, or a mixture thereof; and the polysaccharide derivative has a degree of substitution of about 0.001 to about 3. The products can be useful as anti-deposition and/or anti-graying agents in laundry detergents, and in home care applications.
Method for preparing acylated crosslinked glycosaminoglycans
A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.
COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES
Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME
The present disclosure is related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing the same. The processes of the present invention provide alkylated cyclodextrins with low levels of chloride.
Gel composition and production method therefor
Provided is a production method for a gel composition including steps (1) to (3) mentioned below: step (1) of mixing at room temperature a partial degradation product of the galactose moiety of galactoxyloglucan and an aqueous solvent to obtain a mixture; step (2) of cooling or freezing the mixture obtained in step (1); and step (3) of gelling the mixture cooled or frozen in step (2) by heating to obtain a gel composition that includes the galactose-partial degradation product.
Synthesis of O-antigen oligosaccharide compounds of <i>Helicobacter pylori </i>serotype O2
Disclosed is synthesis of an O-Antigen oligosaccharide compound of Helicobacter pylori serotype O2, belonging to the field of organic synthesis. The disclosure obtains O-antigen disaccharide to tetracosasaccharide of Helicobacter pylori serotype O.sub.2 by chemical synthesis. A chemical synthesis method which is quite conducive to production of a glucose-α-lglucosidic bond is developed in the disclosure by a protectant strategy, temperature effect, solvent effect, and additive effect. The method is applied in synthesis of an O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm. A saccharide conjugate can be prepared from the synthesized O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm together with a carrier protein for immunology researches, playing an important role in preventing and treating Helicobacter pylori.
SULFHYDRYL MODIFIED HYALURONIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF
A sulfhydryl modified hyaluronic acid has a high mercaptan content, and a small change in the molecular mass of the main chain molecule, and has a significantly improved viscosity, water retention, and oxidation resistance. It is prepared from hyaluronic acid modified by acryl-based compounds and polysulfhydryl compounds by means of the Michael addition reaction of mercaptan and conjugated double bonds. The preparation method can flexibly control the structure and composition of a synthesized product, the type and content of the terminal functional group of a large number of compound molecules, etc. The use of a reagent having high biocompatibility effectively controls the production cost and reduces the toxicity during the synthesis.
Engineered glucosyltransferases
Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.
METHOD FOR PRODUCTION OF FUNCTIONAL POLYSACCHARIDE AND COSMETIC COMPOSITION
Provided are a method of manufacturing a functional polysaccharide, the method including: preparing a cell containing a polysaccharide; crushing the cell to extract polysaccharide to the outside of the cell to obtain an extract; and purifying the extract by removing at least one of crude protein, crude fat, and crude powder from the extract, and a cosmetic composition for skin moisturizing or skin elasticity improvement, the cosmetic composition including the functional polysaccharide as an active ingredient.